All In Biotech

Drug Trial Radar · NCT07495007

An Open-label, Randomized, Single-dose, Two-treatment, Four-period, Fully Replicate Crossover Bioequivalence Study in Healthy Female Adult Participants Under Fasting Conditions Comparing the Test Product, Prontogest Solution for IM Injection With the Reference Product, Progesterone Injection

An Open-label, Randomized, Single-dose, Two-treatment, Four-period, Fully Replicate Crossover Bioequivalence Study in Healthy Female Adult Participants Under Fasting Conditions Comparing the Test Product, Prontogest 100mg/2mL Solution for IM Injection With the Reference Product, Progesterone Injection, USP 500mg Per 10mL.

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Nov 10, 2025

Primary completion

Dec 28, 2025

Study completion Dec 28, 2025

Sponsor

Lead sponsor
Zi Diligence BiocenterIndustry
Sponsor type
Industry
Collaborators
Marcyrl Pharmaceutical Industries
First posted
Mar 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Female only, from 40 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Bioequivalence study of two injectable formulation of progesterone in healthy post-menopausal women

Conditions

  • Bioequivalance
  • Post-menopause

Interventions

  • Progesterone IM of 100 mgDrug

    Test Product

  • Progesterone IM of 100 mgDrug

    Reference product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: 72 hours
  2. AUC0-TTime frame: 72 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zi Diligence Biocenter

    Cairo, Cairo Governorate, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.